By Connor Hart
Corcept Therapeutics submitted a new drug application to the Food and Drug Administration for its treatment of hypercortisolism, or Cushing's syndrome, a hormonal disorder that occurs when the body produces too much cortisol.
The Redwood City, Calif., company said Monday its application is based on positive results observed in patients receiving the treatment, relacorilant, in both recent and continuing trials.
"Patients in these studies who received relacorilant experienced improvements in a wide array of hypercortisolism's signs and symptoms, with an acceptable safety burden," the company said.
Chief Executive Joseph Belanoff said the drug's combination of efficacy and safety gives it the potential to become the standard of care for the medical treatment of patients with hypercortisolism.
Cortisol, which is sometimes called the stress hormone, helps to maintain blood pressure, regulate blood sugar, reduce inflammation and convert food into energy. In excessive amounts cortisol can cause health problems including high blood pressure, obesity, elevated blood sugar, severe fatigue and behavior disturbances.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
December 30, 2024 17:48 ET (22:48 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。